{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T13:32:14Z","timestamp":1792762334915,"version":"4.5.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Safety Science"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.ssci.2020.104842","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T09:25:57Z","timestamp":1590053157000},"page":"104842","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations"],"prefix":"10.1016","volume":"129","author":[{"given":"Vangelis","family":"Karalis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ismailos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Karatza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ssci.2020.104842_b0005","unstructured":"Albertson, T.E., 2012. Chapter 51. Chloroquine and Other Aminoquinolines in Poisoning & Drug Overdose 6th eds (editor: Olson KR) The McGraw-Hill Companies, Inc\u00ae2012. New York city (USA)."},{"key":"10.1016\/j.ssci.2020.104842_b0010","unstructured":"Avdic, E., 2020. Chloroquine record. Johns Hopkins ABX Guide. Updated on April 2020. Available at: https:\/\/www.hopkinsguides.com\/hopkins\/view\/Johns_Hopkins_ABX_Guide\/540120\/all\/Chloroquine?q=chloroquine#0."},{"key":"10.1016\/j.ssci.2020.104842_b0015","unstructured":"Avloclor\u00ae Tablets, Summary of Product Characteristics (SmPC), 2016."},{"key":"10.1016\/j.ssci.2020.104842_b0020","unstructured":"Bright, R., 2019. Request for Emergency Use Authorization For Use of Chloroquine Phosphate or Hydroxychloroquine Sulfate Supplied From the Strategic National Stockpile for Treatment of 2019 Coronavirus Disease to the U.S. Food &Drugs Administration (US-FDA). March 2020. Available at: https:\/\/www.fda.gov\/media\/136534\/download."},{"key":"10.1016\/j.ssci.2020.104842_bib181","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.8857","article-title":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial.","author":"Borba","year":"2020","journal-title":"JAMA Network Open"},{"issue":"10","key":"10.1016\/j.ssci.2020.104842_b0025","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40264-018-0689-4","article-title":"Cardiac complications attributed to chloroquine and hydroxychloroquine: a systematic review of the literature","volume":"41","author":"Chatre","year":"2018","journal-title":"Drug Saf."},{"key":"10.1016\/j.ssci.2020.104842_b0030","doi-asserted-by":"crossref","unstructured":"Colson, P., Rolain, J.M., Lagier, J.C., Brouqui, P., Raoult, D., 2020. Chloroquine and hydroxychloroquine as available weapons to fight COVID-19. Int J Antimicrob Agents. 2020 Mar 4:105932. [Epub ahead of print] DOI: 10.1016\/j.ijantimicag.2020.105932.","DOI":"10.1016\/j.ijantimicag.2020.105932"},{"key":"10.1016\/j.ssci.2020.104842_b0035","doi-asserted-by":"crossref","unstructured":"Cortegiani A, Ingoglia G, Ippolito M, Giarratano A, Einav S. A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19. J Crit Care. 2020. pii: S0883-9441(20)30390-7. [Epub ahead of print] DOI: 10.1016\/j.jcrc.2020.03.005.","DOI":"10.1016\/j.jcrc.2020.03.005"},{"key":"10.1016\/j.ssci.2020.104842_b0040","doi-asserted-by":"crossref","unstructured":"Delvecchio R, Higa LM, Pezzuto P, Valad\u00e3o AL, Garcez PP, Monteiro FL, Loiola EC, Dias AA, Silva FJ, Aliota MT, Caine EA, Osorio JE, Bellio M, O'Connor DH, Rehen S, de Aguiar RS, Savarino A, Campanati L, Tanuri A Chloroquine, an Endocytosis Blocking Agent, Inhibits Zika Virus Infection in Different Cell Models. Viruses. 2016;8(12). DOI: 10.1016\/s1473-3099(03)00806-5.","DOI":"10.3390\/v8120322"},{"key":"10.1016\/j.ssci.2020.104842_b0045","doi-asserted-by":"crossref","unstructured":"Fantini, J., Di Scala, C., Chahinian, H., Yahi, N., 2020. Structural and molecular modelling studies reveal a new mechanism of action of chloroquine and hydroxychloroquine against SARS-CoV-2 infection. Int J Antimicrob Agents. 2020 :105960. [Epub ahead of print] DOI: 10.1016\/j.ijantimicag.2020.105960.","DOI":"10.1016\/j.ijantimicag.2020.105960"},{"key":"10.1016\/j.ssci.2020.104842_b0050","unstructured":"FDA Drug Safety Communication: Azithromycin (Zithromax or Zmax) and the risk of potentially fatal heart rhythms. [3-12-2013] Available at."},{"key":"10.1016\/j.ssci.2020.104842_b0055","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases","volume":"Suppl 1","author":"Furst","year":"1996","journal-title":"Lupus."},{"key":"10.1016\/j.ssci.2020.104842_b0060","series-title":"Goodman and Gilman's The Pharmacological Basis of Therapeutics","first-page":"1079","author":"Hardman","year":"2001"},{"key":"10.1016\/j.ssci.2020.104842_b0065","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/s12936-016-1181-1","article-title":"Population pharmacokinetics of a three-day chloroquine treatment in patients with Plasmodium vivax infection on the Thai-Myanmar border","volume":"15","author":"H\u00f6glund","year":"2016","journal-title":"Malar J."},{"issue":"17","key":"10.1016\/j.ssci.2020.104842_b0070","doi-asserted-by":"crossref","first-page":"E450","DOI":"10.1503\/cmaj.200528","article-title":"Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection","volume":"192","author":"Juurlink","year":"2020","journal-title":"CMAJ"},{"issue":"3","key":"10.1016\/j.ssci.2020.104842_b0075","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1128\/AAC.01269-09","article-title":"Pharmacokinetics of chloroquine and monodesethylchloroquine in pregnancy","volume":"54","author":"Karunajeewa","year":"2010","journal-title":"Antimicrob Agents Chemother."},{"issue":"9284","key":"10.1016\/j.ssci.2020.104842_b0080","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(01)06004-4","article-title":"Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases","volume":"358","author":"Klinger","year":"2001","journal-title":"Lancet."},{"key":"10.1016\/j.ssci.2020.104842_b0085","unstructured":"Mayo Clinic. Chloroquine (oral route) record. Available at: https:\/\/www.mayoclinic.org\/drugs-supplements\/chloroquine-oral-route\/description\/drg-20062834."},{"key":"10.1016\/j.ssci.2020.104842_b0090","unstructured":"McEvoy, G.K. (ed.). American Hospital Formulary Service. AHFS Drug Information. American Society of Health-System Pharmacists, Bethesda, MD. 2006, p. 859."},{"issue":"18","key":"10.1016\/j.ssci.2020.104842_b0095","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N Engl. J. Med."},{"issue":"6","key":"10.1016\/j.ssci.2020.104842_b0100","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0750-7658(99)80157-9","article-title":"Chloroquine poisoning with respiratory distress and fatal outcome","volume":"18","author":"Ndiaye","year":"1999","journal-title":"Ann. Fr. Anesth Reanim."},{"key":"10.1016\/j.ssci.2020.104842_b0105","series-title":"Poisoning & Drug Overdose","first-page":"166","author":"Olson","year":"2004"},{"key":"10.1016\/j.ssci.2020.104842_b0110","doi-asserted-by":"crossref","unstructured":"Perinel, S., Launay, M., Botelho-Nevers, \u00c9., Diconne, \u00c9., Louf-Durier, A., Lachand, R., Murgier, M., Page, D., Vermesch, R., Thierry, G., Delavenne, X., 2020. Towards Optimization of Hydroxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. Clin Infect Dis. 2020 Apr 7. pii: ciaa394. [Epub ahead of print] DOI: 10.1093\/cid\/ciaa394.","DOI":"10.1093\/cid\/ciaa394"},{"issue":"20","key":"10.1016\/j.ssci.2020.104842_b0115","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ssci.2020.104842_b0120","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.ijantimicag.2017.05.011","article-title":"Optimal antimalarial dose regimens for chloroquine in pregnancy based on population pharmacokinetic modelling","volume":"50","author":"Salman","year":"2017","journal-title":"Int. J. Antimicrob. Agents."},{"issue":"11","key":"10.1016\/j.ssci.2020.104842_b0125","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/S1473-3099(03)00806-5","article-title":"Effects of chloroquine on viral infections: an old drug against today's diseases?","volume":"3","author":"Savarino","year":"2003","journal-title":"Lancet Infect Dis."},{"issue":"373","key":"10.1016\/j.ssci.2020.104842_b0130","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1007\/BF02811499","article-title":"Extrapyramidal syndrome following chloroquine therapy","volume":"46","author":"Singhi","year":"1979","journal-title":"Indian J. Pediatr."},{"issue":"4","key":"10.1016\/j.ssci.2020.104842_b0135","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jemermed.2004.12.011","article-title":"Are 1\u20132 dangerous? Chloroquine and hydroxychloroquine exposure in toddlers","volume":"28","author":"Smith","year":"2005","journal-title":"J. Emerg. Med."},{"issue":"789","key":"10.1016\/j.ssci.2020.104842_b0140","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1136\/pgmj.67.789.678","article-title":"Massive chloroquine overdose\u2013a survivor","volume":"67","author":"Stiff","year":"1991","journal-title":"Postgrad. Med. J."},{"issue":"18","key":"10.1016\/j.ssci.2020.104842_b0145","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstr\u00f6m","year":"2013","journal-title":"N Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ssci.2020.104842_b0150","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1128\/AAC.01111-08","article-title":"Chloroquine is grossly overdosed and overused but well tolerated in Guinea-bissau","volume":"53","author":"Ursing","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"issue":"7","key":"10.1016\/j.ssci.2020.104842_b0155","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/jps.20343","article-title":"Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: chloroquine phosphate, chloroquine sulfate, and chloroquine hydrochloride","volume":"94","author":"Verbeeck","year":"2005","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ssci.2020.104842_b0160","unstructured":"WHO model prescribing information: drugs used in parasitic diseases, 2nd ed. https:\/\/apps.who.int\/medicinedocs\/en\/d\/Jh2922e\/2.5.1.html."},{"key":"10.1016\/j.ssci.2020.104842_b0165","doi-asserted-by":"crossref","unstructured":"Wong, Y.K., Yang, J., He, Y., 2020. Caution and clarity required in the use of chloroquine for COVID-19. The Lancet. 2020. [Epub ahead of print] DOI: 10.1016\/S2665-9913(20)30093-X.","DOI":"10.1016\/S2665-9913(20)30093-X"},{"key":"10.1016\/j.ssci.2020.104842_b0170","unstructured":"World Health Organization (WHO). INCHEM Chloroquine (PIM 123) record. Reviewed on 1994. Available at: http:\/\/www.inchem.org\/documents\/pims\/pharm\/chloroqu.htm."},{"key":"10.1016\/j.ssci.2020.104842_b0175","doi-asserted-by":"crossref","unstructured":"Yao, .X, Ye, F., Zhang, M., Cui, C., Huang, B., Niu, P., Liu, X., Zhao, L., Dong, E., Song, C., Zhan, S., Lu, R., Li, H., Tan, W., Liu, D., In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020. pii: ciaa237. [Epub ahead of print] DOI: 10.1093\/cid\/ciaa237.","DOI":"10.1093\/cid\/ciaa237"},{"key":"10.1016\/j.ssci.2020.104842_b0180","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1475-2875-13-36","article-title":"Population pharmacokinetics of azithromycin and chloroquine in healthy adults and paediatric malaria subjects following oral administration of fixed-dose azithromycin and chloroquine combination tablets","volume":"13","author":"Zhao","year":"2014","journal-title":"Malar J."}],"container-title":["Safety Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925753520302393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0925753520302393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:15:17Z","timestamp":1760426117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0925753520302393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":37,"alternative-id":["S0925753520302393"],"URL":"https:\/\/doi.org\/10.1016\/j.ssci.2020.104842","relation":{},"ISSN":["0925-7535"],"issn-type":[{"value":"0925-7535","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chloroquine dosage regimens in patients with COVID-19: Safety risks and optimization using simulations","name":"articletitle","label":"Article Title"},{"value":"Safety Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ssci.2020.104842","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104842"}}